Free Trial Information
BioCentury | Oct 23, 2020
Finance

SPAC to the future: an old-time IPO alternative may be back to stay

...its proposed merger with precision oncology play Nuvation Bio Inc....
...said. “But it won’t be for everybody.” Stephen Hansen Nuvation Bio Inc. EcoR1...
Read More
BioCentury | Oct 21, 2020
Deals

With roots in Medivation, Nuvation finds quick route to listing via year’s largest SPAC deal

The team that backed Medivation is returning to the U.S. public markets as Nuvation with a fresh injection of $644 million through a reverse merger with EcoR1’s SPAC Panacea and a PIPE backed by 16...
Read More
BioCentury | Oct 28, 2019
Finance

Nuvation Bio taking multimechanism approach with $275M series A

...develop a pipeline that spans seven mechanisms of action. Omega Funds led the round for Nuvation Bio Inc....
...2019’s largest series A for a biotech, according to BioCentury’s BCIQ database. Paul Bonanos, Associate Editor Medivation Inc. Nuvation Bio Inc....
Read More
Items per page:
1 - 3 of 3
BioCentury | Oct 23, 2020
Finance

SPAC to the future: an old-time IPO alternative may be back to stay

...its proposed merger with precision oncology play Nuvation Bio Inc....
...said. “But it won’t be for everybody.” Stephen Hansen Nuvation Bio Inc. EcoR1...
Read More
BioCentury | Oct 21, 2020
Deals

With roots in Medivation, Nuvation finds quick route to listing via year’s largest SPAC deal

The team that backed Medivation is returning to the U.S. public markets as Nuvation with a fresh injection of $644 million through a reverse merger with EcoR1’s SPAC Panacea and a PIPE backed by 16...
Read More
BioCentury | Oct 28, 2019
Finance

Nuvation Bio taking multimechanism approach with $275M series A

...develop a pipeline that spans seven mechanisms of action. Omega Funds led the round for Nuvation Bio Inc....
...2019’s largest series A for a biotech, according to BioCentury’s BCIQ database. Paul Bonanos, Associate Editor Medivation Inc. Nuvation Bio Inc....
Read More
Items per page:
1 - 3 of 3